Harlan Krumholz
Working to improve the future for those who follow us...
Last synced from Twitter 854d ago
Covid-19 expert Akiko Iwasaki fights a different virus: sexism in science
Shraddha Chakradhar - STAT 85d 30 tweets
To know virologist Akiko Iwasaki is to know that she is passionate about combatting sexism, power imbalance, and toxic behavior in academia.
3
Harlan Krumholz Such an inspiring profile of ; at forefront of science and changing the culture of academia. She is what she appears. Amazing. She says 'if we want to do the best science we can, we need a diverse set of people’ So worth reading. 85d
Ticagrelor vs Clopidogrel and Adverse Events in Patients With Acute Coronary Syndrome Undergoing PCI
Jamanetwork.com 85d 1 tweets
This cohort study compares net risk for ischemic vs hemorrhagic events at 12 months among patients treated with ticagrelor vs clopidogrel during and after percutaneous coronary intervention (PCI) management of acute coronary syndrome (ACS).
2
Harlan Krumholz In , our article comparing ticagrelor and clopidogrel in patients with an acute coronary syndrome undergoing PCI. A remarkable international collaboration. Bottom line: more expensive med not better. 85d
OHDSI Announces 18-Hour Global Symposium Schedule – OHDSI
Ohdsi.org 93d 1 tweets
2
Harlan Krumholz Fantastic international, virtual Global Symposium by group, exemplifying collaborative, open, large-scale, science for observational designs. Spirit of generosity, sharing, and inclusiveness. Next generation science. #JoinTheJourney 93d
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
medRxiv 97d 44 tweets
BACKGROUND WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs. METHODS Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a...
5
Harlan Krumholz This is blockbuster from : 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. 97d
How to Become a Successful Researcher At Every Stage of Your Career
Brighttalk.com 97d 1 tweets
Pursuing a career as a physician-scientist can be daunting, especially as the success rates for securing research grants has declined from 33% to 19%, while the number of grant applications has increa...
1
Harlan Krumholz What a pleasure to have a public conversation w/Dr. Valentin Fuster about mentorship and career development. He has my utmost admiration for his tireless commitment to help others & serve society. The session recording is here: 97d
Learn More About the Phase 3 Study of Our Investigational COVID-19 Vaccine Candidate and Our Commitment to Safety and Transparency
Content Lab U.S. 118d 2 tweets
5
Harlan Krumholz On the #COVID19 transparency front: JNJ has announced that they will share the Clinical Study Report and clinical trial participant data from their vaccine trial with researchers through Open Data Access (YODA) Project. 118d
Six countries, six individuals: resourceful patients navigating medical records in Australia, Canada, Chile, Japan, Sweden and the USA
BMJ Open 125d 3 tweets
In the absence of international standards, widely differing attitudes and laws, medical and social cultures strongly influence whether and how patients may access their medical records in various settings of care. Reviewing records, including the...
1
Harlan Krumholz Terrific, personal piece from top patient advocates 'demonstrating how they are learning to collect, assess & benefit from their personal health info.' From and others. 125d
Vaccine hesitancy: why American values matter
BioCentury 126d 3 tweets
More than a third of Americans tell polls they would not take a vaccine to prevent COVID-19, the most devastating disease in 100 years.
1
Harlan Krumholz Worth reading, policymakers please take note. “Vaccine hesitancy: why American values matter” The argument for transparency and independent evaluation in vaccine evaluation. Brillant and needed piece by 126d
Vaccine Makers Keep Safety Details Quiet, Alarming Scientists
Katie Thomas - Nytimes.com 129d 23 tweets
Researchers say drug companies need to be more open about how vaccine trials are run to reassure Americans who are skittish about getting a coronavirus vaccine.
1
Harlan Krumholz Important reporting by on issues of transparency in the pandemic trials. My comment: “Trust is in short supply… and the more that they can share, the better off we are.” 129d
1
Harlan Krumholz In from : “We’ve never had such an important clinical trial — or series of clinical trials — in recent history…everything should be transparent.” 129d
2020 has been a year without a flu season in the southern hemisphere
The Economist 132d 4 tweets
Efforts to stop covid-19 have had at least one welcome side-effect
2
Harlan Krumholz Interesting from and a compelling graphic … 'Lockdowns have all but eliminated flu season in the southern hemisphere’ 132d
How Foundational Moments In Medicaid’s History Reinforced Rather Than Eliminated Racial Health Disparities | Health Affairs
Healthaffairs.org 141d 5 tweets
1
Harlan Krumholz Fantastic blog by and team… 'Foundational moments in Medicaid’s history led to key facets of current infrastructure of inequities in health care access, along w/racial disparities and disparate health outcomes that followed.’ 136d
Use of Mobile Health Applications in Low-Income Populations
Ahajournals.org 137d 1 tweets
1
Harlan Krumholz Wonderful contribution &team… 'how digital health platform could be customized to better serve low-income patients & supports necessary to facilitate mHealth adoption w/sustained engagement.’ 137d
Air pollution is returning to pre-covid levels
The Economist 139d 15 tweets
This bodes ill for respiratory health
2
Harlan Krumholz Sometimes we forget what a big deal air pollution is… as reported in … deaths likely averted in big cities with air pollution declines during the shut down…not trivial. A risk factor to take seriously. How do we maintain the gain? 138d
Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials - Behnood Bikdeli, César Caraballo, John Welsh, Joseph S Ross, Sanjay Kaul, Gregg W Stone, Harlan M Krumholz, 2020
SAGE Journals 147d 1 tweets
Background/aims Non-inferiority trials are increasing in cardiovascular medicine, with approval of many drugs and devices on the basis of such studies. Surrogat...
3
Harlan Krumholz We took a close look at non-inferiority trials using a surrogate endpoint…led by . Almost all met non-inferiority criteria, but only 5/34 were followed by a clinical outcomes trial and they did not always confirm non-inferiority. 147d
Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events
medRxiv 148d 13 tweets
SARS-CoV-2 has caused a severe, ongoing outbreak of COVID-19 in Massachusetts with 111,070 confirmed cases and 8,433 deaths as of August 1, 2020. To investigate the introduction, spread, and epidemiology of COVID-19 in the Boston area, we sequenced...
1
Harlan Krumholz A masterful preprint using molecular epidemiology to uncover the spread of the coronavirus from the Biogen meeting in Boston. 148d
Observational Study of Convalescent Plasma and FDA Response
Datamethods Discussion Forum 149d 7 tweets
In the preprint Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience from Mayo Clinic by Joyner et al, an observational study of the use of convalescent plasma (CP) for treatment of...
3
Harlan Krumholz From : " The FDA has falsely claimed that 0.35 of COVID-19 patients are benefited from CP, an estimate that not even a highly controlled randomized trial would be able to provide. There is no way to derive the 0.35 from the Mayo Clinic paper.” 149d
Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND)
OUP Academic 149d 3 tweets
Abstract. Evidence derived from existing health-care data, such as administrative claims and electronic health records, can fill evidence gaps in medicine. How
1
Harlan Krumholz Incredibly proud to be part of this amazing collaboration: LEGEND. This is next generation, #bigdata observational research. The pioneers are Ryan You Hripcsak. #openscience 149d
1
Harlan Krumholz "LEGEND embodies a new approach to generating evidence from health-care data that is designed to overcome weaknesses in the current process of answering and publishing (or not) 1 question at a time.” 149d
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan | Circulation: Cardiovascular Quality and Outcomes
Ahajournals.org 151d 1 tweets
1
Harlan Krumholz This important article reveals the difference in patient and doctor perspectives. 'Patients indicated issues of cost were crucial to the decision while physicians and manufacturers expressed that cost was secondary & should be de-emphasized.’ 151d
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing
U.S. Food and Drug Administration 158d 20 tweets
The FDA issued an emergency use authorization to Yale School of Public Health for SalivaDirect, a COVID-19 diagnostic test, using a new method of processing sal
2
Harlan Krumholz And here is the press release: 'The SalivaDirect test for rapid detection of SARS-CoV-2 is yet another testing innovation game changer that will reduce the demand for scarce testing resources’ 158d
Thread by @hmkyale: If you have time at 1ET today, I urge you to listen to @CMichaelGibson on The Democratization of Medicine: Open Access, Social Media, AI, Ap…
Harlan Krumholz - Threadreaderapp.com 166d 1 tweets
Thread by @hmkyale: If you have time at 1ET today, I urge you to listen to @CMichaelGibson on The Democratization of Medicine: Open Access, Media, AI, Apps, and Empowering the Patient as the Future of Clinical Research. I have seen the...